This week, ZenPharm, the Maltese joint venture with Canadian cannabis producer, Zenabis Global, received its Maltese licence to process cannabis for medicinal use and research purposes out of its Hal Far Industrial Estate premises.
Kurt Farrugia, CEO of Malta Enterprise – the national economic development agency that assisted the company to set up locally – considers this “an important milestone for Malta’s medical cannabis industry.”
“We are gaining momentum with the production of cannabis for medical use in Malta,” he wrote. “Zenabis – a Maltese joint venture and partner of Zenpharm, have received a licence for the production of medical cannabis in their facility in Hal Far, Malta.”
The CEO said that the issuing of the second licence for the production of cannabis for medical use shows that “Malta is becoming a centre of excellence in such an important emerging sector.”
“Those companies strive hard to achieve the Medicine's Authority pharmaceutical standards. Now that they do, patients can rest assured that the Made in Malta product is top quality. A gold standard for the industry. This is indeed a proud moment.”
Through its licence, ZenPharm plans to ship around 500kg of cannabis out of Malta annually to EU countries, with the largest market being Germany.
Featured Image:
Kurt Farrugia / LinkedIn
Tech companies back AI support in recruitment, underscore rising importance of AI literacy
Some spoke of concerns they have over prospective employees using AI in their applications.
Nikolaos Fertakis returns to HSBC Malta as interim Chief Risk Officer
Nikolaos Fertakis previously served as HSBC Bank Malta’s Chief Operating Officer.
The circular economy conversation is shifting, agency CEO says
Keeping materials in use for longer is no longer just about waste reduction, he said.
Emmanuel Agius appointed President of the St John’s Co-Cathedral Foundation
This marks the fourth occasion on which he has been appointed to this role.
